RE:Eli Lilly (LLY) Scraps Phase III study-Solanezumab-ADGV,
In addition to the Phase 1a trial news release that you shared on the effect of RVX-208 on AB40 levels after 7 days of dosing, Resverlogix looked at AB40 levels in the 12 week long ASSERT trial (
news release) and also saw a significant effect vs. baseline and placebo. I'm not sure if Resverlogix ever disclosed AB40 levels from the ~6month long SUSTAIN or ASSURE trials. However, they have a Neurodegenative Disease Clinical Advisory Board that they set up in 2012 (and is still listed on their web page) and we've been told that within BETonMACE, there is an embedded Alzheimer's study....but I don't recall the endpoints off the top of my head. I would expect them to look at whatever they can from these patients dosed for up to 2 years in BETonMACE, including AB40 and cognitive function tests.
BearDownAZ